[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

VPAResearch: Market Research Reports

VPA Research is one of the global pharmaceutical companies specialized in analysis of clinical trials. We provide leading insights into global Pharma products, pipeline research, companies and drugs markets.

Publications found: 58,333
Sort by:

Influenza A H7N9 Infection R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Influenza A H7N9 Infection Pipeline Overview The Q4 Influenza A H7N9 Infection pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline...

October 2020 116 pages

Influenza A Virus H3N2 Subtype Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,979.00

Influenza A Virus H3N2 Subtype Infections Pipeline Overview The Q4 Influenza A Virus H3N2 Subtype Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly...

October 2020 165 pages

Influenza B Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,979.00

Influenza B Infections Pipeline Overview The Q4 Influenza B Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs...

October 2020 162 pages

Insulin Resistance R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Insulin Resistance Pipeline Overview The Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs und...

October 2020 53 pages

Japanese Encephalitis R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Japanese Encephalitis Pipeline Overview The Q4 Japanese Encephalitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...

October 2020 51 pages

Kaposi Sarcoma R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Kaposi Sarcoma Pipeline Overview The Q4 Kaposi Sarcoma pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...

October 2020 72 pages

Kidney Transplant Rejection R&D Pipeline Analysis Report, Q4 2020

US$ 1,979.00

Kidney Transplant Rejection Pipeline Overview The Q4 Kidney Transplant Rejection pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of...

October 2020 154 pages

Klebsiella pneumoniae Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,979.00

Klebsiella pneumoniae Infections Pipeline Overview The Q4 Klebsiella pneumoniae Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes t...

October 2020 143 pages

Lassa Fever R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Lassa Fever Pipeline Overview The Q4 Lassa Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for...

October 2020 65 pages

Leishmaniasis (Kala-Azar) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Leishmaniasis (Kala-Azar) Pipeline Overview The Q4 Leishmaniasis (Kala-Azar) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of...

October 2020 93 pages

Liver Transplant Rejection R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Liver Transplant Rejection Pipeline Overview The Q4 Liver Transplant Rejection pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of d...

October 2020 51 pages

Lung Transplant Rejection R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Lung Transplant Rejection Pipeline Overview The Q4 Lung Transplant Rejection pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of dru...

October 2020 64 pages

Lyme Disease R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Lyme Disease Pipeline Overview The Q4 Lyme Disease pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...

October 2020 68 pages

Marburgvirus Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Marburgvirus Infections Pipeline Overview The Q4 Marburgvirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of dru...

October 2020 103 pages

Measles R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Measles Pipeline Overview The Q4 Measles pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Measles...

October 2020 54 pages

Meningitis R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Meningitis Pipeline Overview The Q4 Meningitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for M...

October 2020 64 pages

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Overview The Q4 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline report is part of the VPA 110 Infectio...

October 2020 54 pages

Microscopic Polyangiitis (MPA) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Microscopic Polyangiitis (MPA) Pipeline Overview The Q4 Microscopic Polyangiitis (MPA) pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipel...

October 2020 42 pages

Middle East Respiratory Syndrome (MERS) R&D Pipeline Analysis Report, Q4 2020

US$ 1,979.00

Middle East Respiratory Syndrome (MERS) Pipeline Overview The Q4 Middle East Respiratory Syndrome (MERS) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly revi...

October 2020 104 pages

Mumps R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Mumps Pipeline Overview The Q4 Mumps pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Mumps, prov...

October 2020 40 pages

Myasthenia Gravis R&D Pipeline Analysis Report, Q4 2020

US$ 1,979.00

Myasthenia Gravis Pipeline Overview The Q4 Myasthenia Gravis pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under develop...

October 2020 162 pages

Neisseria meningitidis Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Neisseria meningitidis Infections Pipeline Overview The Q4 Neisseria meningitidis Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes...

October 2020 84 pages

Onychomycosis (Tinea Unguium) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Onychomycosis (Tinea Unguium) Pipeline Overview The Q4 Onychomycosis (Tinea Unguium) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pip...

October 2020 76 pages

Osteomyelitis R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Osteomyelitis Pipeline Overview The Q4 Osteomyelitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...

October 2020 52 pages

Peanut Allergy R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Peanut Allergy Pipeline Overview The Q4 Peanut Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development f...

October 2020 134 pages

Pemphigus Vulgaris R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Pemphigus Vulgaris Pipeline Overview The Q4 Pemphigus Vulgaris pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under devel...

October 2020 72 pages

Pertussis (Whooping Cough) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Pertussis (Whooping Cough) Pipeline Overview The Q4 Pertussis (Whooping Cough) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline...

October 2020 112 pages

Phenylketonuria (PKU) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Phenylketonuria (PKU) Pipeline Overview The Q4 Phenylketonuria (PKU) pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of dru...

October 2020 81 pages

Pituitary ACTH Hypersecretion R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Pituitary ACTH Hypersecretion Pipeline Overview The Q4 Pituitary ACTH Hypersecretion pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the...

October 2020 43 pages

Plague R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Plague Pipeline Overview The Q4 Plague pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Plague, p...

October 2020 52 pages

Polio (Poliomyelitis) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Polio (Poliomyelitis) Pipeline Overview The Q4 Polio (Poliomyelitis) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...

October 2020 101 pages

Pompe Disease R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Pompe Disease Pipeline Overview The Q4 Pompe Disease pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under develop...

October 2020 101 pages

Post Menopausal Osteoporosis R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Post Menopausal Osteoporosis Pipeline Overview The Q4 Post Menopausal Osteoporosis pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the p...

October 2020 132 pages

Progressive Multifocal Leukoencephalopathy R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Progressive Multifocal Leukoencephalopathy Pipeline Overview The Q4 Progressive Multifocal Leukoencephalopathy pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterl...

October 2020 45 pages

Pyelonephritis R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Pyelonephritis Pipeline Overview The Q4 Pyelonephritis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...

October 2020 81 pages

Rabies R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Rabies Pipeline Overview The Q4 Rabies pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Rabies, p...

October 2020 97 pages

Ragweed Pollen Allergy R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Ragweed Pollen Allergy Pipeline Overview The Q4 Ragweed Pollen Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs und...

October 2020 41 pages

Resistant Pseudomonas aeruginosa Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Resistant Pseudomonas aeruginosa Infections Pipeline Overview The Q4 Resistant Pseudomonas aeruginosa Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarte...

October 2020 61 pages

Rhinovirus Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Rhinovirus Infections Pipeline Overview The Q4 Rhinovirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...

October 2020 71 pages

Rotavirus Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Rotavirus Infections Pipeline Overview The Q4 Rotavirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs und...

October 2020 58 pages

Rubella (German Measles) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Rubella (German Measles) Pipeline Overview The Q4 Rubella (German Measles) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of d...

October 2020 52 pages

Schistosomiasis R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Schistosomiasis Pipeline Overview The Q4 Schistosomiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under develop...

October 2020 48 pages

Severe Acute Respiratory Syndrome (SARS) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Severe Acute Respiratory Syndrome (SARS) Pipeline Overview The Q4 Severe Acute Respiratory Syndrome (SARS) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly re...

October 2020 131 pages

Sjogren Syndrome R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Sjogren Syndrome Pipeline Overview The Q4 Sjogren Syndrome pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under developme...

October 2020 147 pages

Smallpox R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Smallpox Pipeline Overview The Q4 Smallpox pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Small...

October 2020 64 pages

Streptococcus pyogenes Infections R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Streptococcus pyogenes Infections Pipeline Overview The Q4 Streptococcus pyogenes Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes...

October 2020 45 pages

Tetanus R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Tetanus Pipeline Overview The Q4 Tetanus pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Tetanus...

October 2020 132 pages

Tinea pedis (Athlete Foot) R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Tinea pedis (Athlete Foot) Pipeline Overview The Q4 Tinea pedis (Athlete Foot) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline...

October 2020 40 pages

Toxoplasmosis R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Toxoplasmosis Pipeline Overview The Q4 Toxoplasmosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...

October 2020 30 pages

Tularaemia R&D Pipeline Analysis Report, Q4 2020

US$ 1,529.00

Tularaemia Pipeline Overview The Q4 Tularaemia pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for T...

October 2020 45 pages

Filters

Search

Categories

60
12,968
1,223
4,429
2
1
10,890
2,818
15,138
67
8,921
1
1,229
586

Publishers

58,333

Regions

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
58,296

Price

Date

Pages

Offers